The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
Cardiovascular disease (CVD) is the leading cause of mortality in patients with type 2 diabetes mellitus (DM) worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed for treating patients with type...
Conclusions/Relevance: The participants included in this study had various basal metabolic indices, ages, glomerular filtration rates, and diabetic status characteristics. Although these patients were quite different, after the administration of SGLT2i, the studies showed a beneficial effect in reducing CVD mortality and morbidity in patients...
Impact of left bundle branch block on heart failure with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36932820/
In patients admitted with decompensated heart failure with preserved ejection fraction, left bundle branch block is associated with increased odds of cardiac arrest, mechanical circulatory support requirement, device implantation and...
Conclusion: In patients admitted with decompensated heart failure with preserved ejection fraction, left bundle branch block is associated with increased odds of cardiac arrest, mechanical circulatory support requirement, device implantation and mean cost of hospitalization but decreased odds of in-hospital mortality.
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01789-5
Background Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a...
Conclusion: Our results appear to contradict the mainstream concepts regarding the cardiovascular effects of SGLT2i since we found no significant therapeutic benefits in SGLT2i to reduce the incidence of ACS, PAOD, or IS when compared to placebo or oral hypoglycemic drugs.
Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36912450/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2i and statins or for specific drug pairs.
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/pii/S0019483223000433?via=ihub
Available online 11 March 2023 Author links open overlay panel Mainak Banerjee a 1 , Rimesh Pal b 1 , Kirthana Nair b , Satinath Mukhopadhyay a Show more To...
Conclusions: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.